Bevarest 100mg/4ml INJECTION ( Emcure ) - Blueberry pharmaceuticals

1. BEVAREST 100mg 4ml | BEVACIZUMAB |Blueberry pharmaceuticals BEVAREST 100mg 4ml BEVAREST 100MG INDICATION : Bevarest 100mg 4ml is a brand name of Bevacizumab, categorized as monoclonal anti-body & anti-angiogenesis Bevarest is a combined human monoclonal antibody IgG1, that predicament to and prohibits the biological activity of human vascular endothelial growth factor (VEGF) Bevarest 100mg 4ml MECHANISM OF ACTION Bevarest 100mg 4ml comprises an active compound like Bevacizumab which binds to VEGF and avoid the communication of VEGF to its receptors like Flt-1 & KDR) present on the surface of the cells This interaction prevents endothelial cell multiplication and new blood vessel production

2. occurs Thus in counts discontinuation of metastatic tumor cells growth happens PHARMACOKINETICS The pharmacokinetic form of Bevarest 100mg 4ml is assayed by measuring total serum Bevacizumab concentration. DOSAGE AND ADMINISTRATION KEY POINT Bevarest 100mg 4ml do not administered before at least 28 days following surgery and the wound is completely cured METASTATIC COLORECTAL CARCINOMA The prescribed dosage of Bevarest 100mg 4ml by concomitant with 5-fluorouracil based chemotherapy 5mg/kg of Bevarest for every 2 weeks IV in concomitant with bolus IFL 10mg/kg of Bevarest for every 2 weeks IV in combination with FOLFOX4 5mg/kg IV Bevarest for every 2 weeks or 7.5 mg/kg Bevarest as IV every 3 weeks by concurrently used with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy NON-SMALL CELL LUNG CANCER The recommended dosage of Bevarest 100mg 4ml is 15mg/kg IV for every 3 weeks by combining with carboplatin and paclitaxel

3. GLIOBLASTOMA 10mg/kg of Bevarest administered IV for every 2 weeks METASTATIC RENAL CELL CANCER The prescribed dosage of Bevarest 100mg 4ml is 10mg/kg IV for every 2 weeks by concurrent use with interferon alfa METASTATIC CERVICAL CANCER The prescribed dosage of Bevarest 100mg 4ml ; 15mg/kg of Bevarest given intravenously for every 3 weeks by combining with paclitaxel and cisplatin or with paclitaxel and topotecan EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER Platinum opposing The recommended dosage of Bevarest 100mg 4ml ; 10mg/kg of Bevarest for every 2 weeks by concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan Or The recommended dosage of Bevarest ; 15mg/kg of Bevarest given through IV for every 3 weeks by combining with topotecan Platinum responsive The recommended dosage of Bevarest 100mg 4ml ; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles The recommended dosage of

4. Bevarest ; 15mg/kg of Bevarest given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles PREPARATION & ADMINISTRATION Bevarest 100mg 4ml is intravenous solution At initial infusion: given IV infusion over 90 minutes Following infusions: give second infusion over 60 minutes, if tolerated Administer all following infusion over 30minutes Bevarest IV infusion is prepared in aseptic condition Bevarest 100mg 4ml containing 16ml solution whereas 100mg containing 4ml Bevarest dilute into 100ml of 0.9% NS Do not dilute with dextrose solution Discard the remaining portion which is left in a vial SIDE EFFECTS Gastrointestinal perforation and fistulae, Surgery and wound healing complication, Hemorrhage, Arterial thromboembolic events, Venous thromboembolic events, Hypertension, Posterior reversible encephalopathy syndrome, Proteinuria, Infusion reactions, Ovarian failure, Congestive heart failure, Neutropenia, mucosal neuropathy, Epistaxis, erythrodysaesthesia Renal injury & inflammation, infection, CONTACTS Phone : +91-97890 77748 Email: info@blueberrypharma.com WEBSITE: https://blueberrypharma.com/bevacizumab.php https://blueberrypharma.com/bevarest.php